Trial site
Hospital Sultan Ismail
Johor Bahru, 81100, MalaysiaNot linked to an institution yet
- 18running trials
- 7closed trials
The trials here
What the 25 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 2/35 trials
- Phase 43 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 21 trial
- Status
- Active, not recruiting15 trials
- Completed6 trials
- Recruiting2 trials
- Enrolling by invitation1 trial
- Terminated1 trial
- Lead sponsor
- Janssen Research & Development, LLC7 trials
- Boehringer Ingelheim4 trials
- Celldex Therapeutics2 trials
- Gilead Sciences2 trials
- LEO Pharma2 trials
- and 7 more
Running trials
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· Phase 3· Janssen Research & Development, LLC· Source
Enrolling by invitation
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392· Phase 3· Celldex Therapeutics· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023· Phase 3· Celldex Therapeutics· Source
Active, not recruiting
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
NCT05800015· Phase 2/3· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05785767· Phase 2/3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· Phase 3· Gilead Sciences· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299· Phase 3· Gilead Sciences· Source
Active, not recruiting
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210· Phase 4· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499· Phase 2/3· Hoffmann-La Roche· Source
Active, not recruiting
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022· Phase 1/2· Dizal Pharmaceuticals· Source
Active, not recruiting
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
NCT03886246· Phase 2· LEO Pharma· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Randomised Evaluation of Sodium Dialysate Levels on Vascular Events
NCT02823821· Phase 4· University of Sydney· Source
Contact: Grace Balicki
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error